Advanced therapy medicinal products: current and future perspectives.

Area of Science:

• Biotechnology and Pharmaceutical Sciences
• Clinical Trial Design and Regulation
• Health Economics and Market Access

Background:

• Advanced therapy medicinal products (ATMPs) represent innovative medical treatments, including gene therapy, somatic cell therapy, and tissue-engineered products.
• While offering significant health benefits, ATMPs pose potential challenges to pharmaceutical budgets.

Purpose of the Study:

• To characterize the landscape of ATMPs currently in clinical development.
• To discuss the future market access implications for these novel therapies.

Main Methods:

• A comprehensive search of clinical trial databases including EudraCT, ClinicalTrials.gov, and ICTRP.
• Classification of trials by ATMP category, development phase, and disease area according to European regulation EC No. 1394/2007.

Main Results:

• 939 ATMP clinical trials were identified, with 85% ongoing and predominantly in early development phases (64.3% in Phase I/II).
• Somatic cell therapies constituted the largest category (53.6%), followed by tissue-engineered products (22.8%) and gene therapies (22.4%).
• Cancer (24.8%) and cardiovascular diseases (19.4%) were the most common disease areas, with many trials enrolling fewer than 25 patients, necessitating novel trial methodologies.

Conclusions:

• ATMPs are a rapidly expanding field with the potential for earlier market entry than traditional therapies due to their curative potential.
• The unique nature of ATMPs supports the adoption of innovative clinical trial designs to facilitate early access.
• ATMPs are anticipated to significantly influence future pharmaceutical spending and require careful consideration of payer expectations and post-launch evidence generation.